- $663.72m
- $286.05m
US charges British billionaire Joe Lewis with insider trading (updated)
Solid Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Solid Biosciences Says Ends Q1 With About $185.5 Mln In Cash
Solid Biosciences Inc expected to post a loss of $2.05 a share - Earnings Preview
Brief: Solid Biosciences Inc - Company Ends 2022 With Approximately $213.7 Million In Cash And Investments Anticipated Cash Runway Into 2025
Solid Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Solid Biosciences Maintains Less Than $1.0 Mln, In Checking Accounts At Silicon Valley Bank
Solid Biosciences Inc expected to post a loss of $1.65 a share - Earnings Preview
Brief: Solid Biosciences Inc Files For Resale Of Up To About 12 Million Shares Of Common Stock By Selling Stockholders
Brief: Solid Biosciences, Phlox Therapeutics Collaborates On Accelerating New Therapies For Rare Cardiac Diseases
Brief: Solid Biosciences Outlines Strategy For Leadership In Precision Genetic Medicines With Focus On Neuromuscular And Cardiac Diseases
Brief: Solid Biosciences Appoints Kevin Tan, Cfa, As Chief Financial Officer
Brief: Solid Biosciences Inc Expects To Report Cash And Investments Of About $214 Mln As Of December 31, 2022
Brief: Solid Biosciences Announces Closing Of Acquisition Of AavantiBio, Concurrent $75 Mln Private Placement
Brief: Solid Biosciences Announces Stockholder Approval Of Acquisition Of Aavantibio
Solid Biosciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Solid Biosciences Ends Third Quarter With About $142.2 Million In Cash
Solid Biosciences Inc expected to post a loss of $2.67 a share - Earnings Preview
Brief: Solid Biosciences Announces A 1-For-15 Reverse Stock Split